18F-PSMA-1007 POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF RECURRENT PROSTATE CANCER: CLINICAL OBSERVATION
M. B. Dolgushin,
N. A. Meshcheryakova,
A. A. Odzharova,
V. B. Matveev,
D. I. Nevzorov,
O. E. Platonova,
P. V. Kochergin https://doi.org/10.17650/1726-9776-2018-14-3-134-138
Abstract
Objective: demonstration of possibilities of 18F-prostate specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) for diagnostic prostate cancer recurrence.
The article presents clinical observation of the patient with prostate cancer biochemical recurrence after the multiple treatment. 18F-PSMA-1007 PET/CT demonstrates high sensitivity in prostate cancer recurrence diagnostic, in particular with low prostatic specific antigen level.
About the Authors
M. B. Dolgushin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
N. A. Meshcheryakova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
D. I. Nevzorov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
O. E. Platonova
Medicina
Russian Federation
10 2nd Tverskoy-Yamskoy Pereulok, Moscow 125047.
Competing Interests:
Russian Federation
10 2nd Tverskoy-Yamskoy Pereulok, Moscow 125047.
Competing Interests:
No conflict of interest.
P. V. Kochergin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
References
1. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005;288(5):C975–81. DOI: 10.1152/ajpcell.00506.2004. PMID: 15840561.
2. Wright G.L. Jr, Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1(1):18–28. PMID: 21224086.
3. Liu H., Rajasekaran A.K., Moy P. et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58(18):4055–60. PMID: 9751609.
4. Giesel F.L., Hadaschik B., Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44(4):678–88. DOI: 10.1007/s00259-016-3573-4. PMID: 27889802.
5. Cho S.Y., Gage K.L., Mease R.C. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53(12):1883–91. DOI: 10.2967/jnumed.112.104661. PMID: 23203246.
6. Szabo Z., Mena E., Rowe S.P. et al. Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015;17(4):565–74. DOI: 10.1007/s11307-015-0850-8. PMID: 25896814.
7. Kratochwil C., Giesel F.L., Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med 2016;57(8):1170–6. DOI: 10.2967/jnumed.115.171397.
8. Ahmadzadehfar H., Eppard E., Kürpig S. et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016;7(11):12477–88. DOI: 10.18632/oncotarget.7245. PMID: 26871285.
9. Kratochwil C, Bruchertseifer F., Giesel F.L. et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016.
10. Cardinale J., Schäfer M., Benesová M. et al. Preclinical evaluation of [18F] PSMA1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med 2016.
11. Giesel F.L., Hadaschik B., Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer. Eur J Nucl Med Mol Imaging 2017.
12. Zaman M.U., Fatima N., Zaman A. et al. Diagnostic challenges in prostate cancer and 68Ga-PSMA PET imaging: a game changer? Asian Pacific J Cancer Prev 2017;18(10):2625–8. DOI: 10.22034/APJCP.2017.18.10.2625. PMID: 29072055.
Review
For citations:
Dolgushin M.B., Meshcheryakova N.A., Odzharova A.A., Matveev V.B., Nevzorov D.I., Platonova O.E., Kochergin P.V. 18F-PSMA-1007 POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF RECURRENT PROSTATE CANCER: CLINICAL OBSERVATION. Cancer Urology. 2018;14(3):134-138. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-134-138
Views:
1044
Email this article 